|
1
|
Peng JC, Zhong L and Ran ZH: Primary
lymphomas in the gastrointestinal tract. J Dig Dis. 16:169–176.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang T, Gui W and Shen Q: Primary
gastrointestinal non-Hodgkin's lymphoma: Clinicopathological and
prognostic analysis. Med Oncol. 27:661–666. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cogliatti SB, Schmid U, Schumacher U,
Eckert F, Hansmann ML, Hedderich J, Takahashi H and Lennert K:
Primary B-cell gastric lymphoma: A clinicopathological study of 145
patients. Gastroenterology. 101:1159–1170. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koch P, del Valle F, Berdel WE, Willich
NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann
J, Temmesfeld A, et al: Primary gastrointestinal non-Hodgkin's
lymphoma: I. Anatomic and histologic distribution, clinical
features, and survival data of 371 patients registered in the
German multicenter study GIT NHL 01/92. J Clin Oncol. 19:3861–3873.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Papaxoinis G, Papageorgiou S, Rontogianni
D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C,
Xiros N and Economopoulos T: Primary gastrointestinal non-Hodgkin's
lymphoma: A clinicopathologic study of 128 cases in Greece. A
hellenic cooperative oncology group study (HeCOG). Leuk Lymphoma.
47:2140–2146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suresh B, Asati V, Lakshmaiah KC, Babu G,
Lokanatha D, Jacob LA, Lokesh KN, Rudresh AH, Rajeev LK, Smitha S,
et al: Primary gastrointestinal diffuse large B-cell lymphoma: A
prospective study from South India. South Asian J Cancer. 8:57–59.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen K and Rajewsky N: The evolution of
gene regulation by transcription factors and microRNAs. Nat Rev
Genet. 8:93–103. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu FQ, Zeng L, Tang N, Tang YP, Zhou BP,
Li FF, Wu WG, Zeng XB and Peng SS: MicroRNA-155 downregulation
promotes cell cycle arrest and apoptosis in diffuse large B-cell
lymphoma. Oncol Res. 24:415–427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhuang H, Shen J, Zheng Z, Luo X, Gao R
and Zhuang X: MicroRNA-146a rs2910164 polymorphism and the risk of
diffuse large B cell lymphoma in the Chinese Han population. Med
Oncol. 31:3062014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berglund M, Hedström G, Amini RM, Enblad G
and Thunberg U: High expression of microRNA-200c predicts poor
clinical outcome in diffuse large B-cell lymphoma. Oncol Rep.
29:720–724. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ivey KN and Srivastava D: microRNAs as
developmental regulators. Cold Spring Harb Perspect Biol.
7:a0081442015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Larrabeiti-Etxebarria A, Lopez-Santillan
M, Santos-Zorrozua B, Lopez-Lopez E and Garcia-Orad A: Systematic
review of the potential of MicroRNAs in diffuse large B cell
lymphoma. Cancers (Basel). 11(pii): E1442019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koscianska E and Krzyzosiak WJ: Current
understanding of the role of microRNAs in spinocerebellar ataxias.
Cerebellum Ataxias. 1:72014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bi N, Cao J, Song Y, Shen J, Liu W, Fan J,
He J, Shi Y, Zhang X, Lu N, et al: A microRNA signature predicts
survival in early stage small-cell lung cancer treated with surgery
and adjuvant chemotherapy. PLoS One. 9:e913882014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang W, Xu P, Wang H, Niu Z, Zhu D, Lin Q,
Tang L and Ren L: MicroRNA-150 suppresses triple-negative breast
cancer metastasis through targeting HMGA2. Onco Targets Ther.
11:2319–2332. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yokobori T, Suzuki S, Tanaka N, Inose T,
Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H and Kuwano
H: miR-150 is associated with poor prognosis in esophageal squamous
cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci.
104:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma Y, Zhang P, Wang F, Zhang H, Yang J,
Peng J, Liu W and Qin H: miR-150 as a potential biomarker
associated with prognosis and therapeutic outcome in colorectal
cancer. Gut. 61:1447–1453. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee KH, Lee JK, Choi DW, Do IG, Sohn I,
Jang KT, Jung SH, Heo JS, Choi SH and Lee KT: Postoperative
prognosis prediction of pancreatic cancer with seven microRNAs.
Pancreas. 44:764–768. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang S, Chen Y, Wu W, Ouyang N, Chen J,
Li H, Liu X, Su F, Lin L and Yao Y: miR-150 promotes human breast
cancer growth and malignant behavior by targeting the pro-apoptotic
purinergic P2X7 receptor. PLoS One. 8:e807072013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yin QW, Sun XF, Yang GT, Li XB, Wu MS and
Zhao J: Increased expression of microRNA-150 is associated with
poor prognosis in non-small cell lung cancer. Int J Clin Exp
Pathol. 8:842–846. 2015.PubMed/NCBI
|
|
24
|
Dezhong L, Xiaoyi Z, Xianlian L, Hongyan
Z, Guohua Z, Bo S, Shenglei Z and Lian Z: miR-150 is a factor of
survival in prostate cancer patients. J BUON. 20:173–179.
2015.PubMed/NCBI
|
|
25
|
Dettmer MS, Perren A, Moch H, Komminoth P,
Nikiforov YE and Nikiforova MN: MicroRNA profile of poorly
differentiated thyroid carcinomas: New diagnostic and prognostic
insights. J Mol Endocrinol. 52:181–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang W, Wang X, Zhang Y, Wang D, Gao H,
Wang L and Gao S: Prognostic role of microRNA-150 in various
carcinomas: A meta-analysis. Onco Targets Ther. 9:1371–1379. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Monticelli S, Ansel KM, Xiao C, Socci ND,
Krichevsky AM, Thai TH, Rajewsky N, Marks DS, Sander C, Rajewsky K,
et al: MicroRNA profiling of the murine hematopoietic system.
Genome Biol. 6:R712005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Szurián K, Csala I, Piurkó V, Deák L,
Matolcsy A and Reiniger L: Quantitative miR analysis in chronic
lymphocytic leukaemia/small lymphocytic lymphoma-proliferation
centres are characterized by high miR-92a and miR-155 and low
miR-150 expression. Leuk Res. 58:39–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang M, Yang W, Li M and Li Y: Low
expression of miR-150 in pediatric intestinal Burkitt lymphoma. Exp
Mol Pathol. 96:261–266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gebauer N, Kuba J, Senft A, Schillert A,
Bernard V and Thorns C: MicroRNA-150 Is up-regulated in extranodal
marginal zone lymphoma of MALT type. Cancer Genomics Proteomics.
11:51–56. 2014.PubMed/NCBI
|
|
31
|
Tomonaga M: Outline and direction of
revised WHO classification of tumors of haematopoietic and lymphoid
tissues. Rinsho Ketsueki. 50:1401–1406. 2009.(In Japanese).
PubMed/NCBI
|
|
32
|
Huang J, Jiang W, Xu R, Huang H, Lv Y, Xia
Z, Sun X, Guan Z, Lin T and Li Z: Primary gastric non-Hodgkin's
lymphoma in Chinese patients: Clinical characteristics and
prognostic factors. BMC Cancer. 10:3582010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Horwitz SM, Zelenetz AD, Gordon LI, Wierda
WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC,
Fayad LE, et al: NCCN guidelines insights: Non-Hodgkin's lymphomas,
version 3.2016. J Natl Compr Canc Netw. 14:1067–1079. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheson BD, Pfistner B, Juweid ME, Gascoyne
RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca
E, et al: Revised response criteria for malignant lymphoma. J Clin
Oncol. 25:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ferreri AJ and Montalban C: Primary
diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol
Hematol. 63:65–71. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dawson IM, Cornes JS and Morson BC:
Primary malignant lymphoid tumours of the intestinal tract. Report
of 37 cases with a study of factors influencing prognosis. Br J
Surg. 49:80–89. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nakamura S and Iida M: Molecular genetics
in primary gastrointestinal lymphomas. Fukuoka Igaku Zasshi.
99:123–130. 2008.(In Japanese). PubMed/NCBI
|
|
38
|
Nakamura S, Matsumoto T, Nakamura S, Jo Y,
Fujisawa K, Suekane H, Yao T, Tsuneyoshi M and Iida M: Chromosomal
translocation t(11;18)(q21;q21) in gastrointestinal mucosa
associated lymphoid tissue lymphoma. J Clin Pathol. 56:36–42. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lan H, Lu H, Wang X and Jin H: MicroRNAs
as potential biomarkers in cancer: Opportunities and challenges.
Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Watanabe A, Tagawa H, Yamashita J, Teshima
K, Nara M, Iwamoto K, Kume M, Kameoka Y, Takahashi N, Nakagawa T,
et al: The role of microRNA-150 as a tumor suppressor in malignant
lymphoma. Leukemia. 25:1324–1334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang L, Lin J, Ye Y, Oba T, Gentile E,
Lian J, Wang J, Zhao Y, Gu J, Wistuba II, et al: Serum MicroRNA-150
predicts prognosis for early-stage non-small cell lung cancer and
promotes tumor cell proliferation by targeting tumor suppressor
gene SRCIN1. Clin Pharmacol Ther. 103:1061–1073. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
He Y, Jiang X and Chen J: The role of
miR-150 in normal and malignant hematopoiesis. Oncogene.
33:3887–3893. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fayyad-Kazan H, Bitar N, Najar M, Lewalle
P, Fayyad-Kazan M, Badran R, Hamade E, Daher A, Hussein N, ElDirani
R, et al: Circulating miR-150 and miR-342 in plasma are novel
potential biomarkers for acute myeloid leukemia. J Transl Med.
11:312013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Katada T, Ishiguro H, Kuwabara Y, Kimura
M, Mitui A, Mori Y, Ogawa R, Harata K and Fujii Y: microRNA
expression profile in undifferentiated gastric cancer. Int J Oncol.
34:537–542. 2009.PubMed/NCBI
|
|
45
|
Song JL, Wei XL, Zhang YK, Hao XX, Huang
WM, Wei Q, Wei YQ and Feng R: The prognostic value of the
international prognostic index, the national comprehensive cancer
network IPI and the age-adjusted IPI in diffuse large B cell
lymphoma. Zhonghua Xue Ye Xue Za Zhi. 39:739–744. 2018.(In
Chinese). PubMed/NCBI
|
|
46
|
van Imhoff GW, Boerma EJ, van der Holt B,
Schuuring E, Verdonck LF, Kluin-Nelemans HC and Kluin PM:
Prognostic impact of germinal center-associated proteins and
chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
J Clin Oncol. 24:4135–4142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Coiffier B, Lepage E, Briere J, Herbrecht
R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G,
Gaulard P, et al: CHOP chemotherapy plus rituximab compared with
CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med. 346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
